2014 Press Releases

Receive E-mail AlertsEmail Alerts
Sign up to receive e-mail alerts whenever MannKind has a news release. Just enter your e-mail address and click submit.
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
09/29/14MannKind Announces Receipt of $150 Million Licensing Upfront Payment
VALENCIA, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it had received a $150 million upfront payment in connection with an exclusive worldwide collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. About MannKind Corporation MannKind Corporation (Nasdaq:MNKD) focuses on... 
Printer Friendly Version
09/24/14MannKind Announces Closing of Global Licensing Agreement With Sanofi
VALENCIA, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The closing follows completion of the US Federal Trade Commission's review of the transaction under the Hart-Scott-Rodino Act and the co... 
Printer Friendly Version
09/02/14MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
VALENCIA, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 12:55 PM (ET) at the Grand Hyatt Hotel in New York City. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at ht... 
Printer Friendly Version
08/11/14Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
Paris and Valencia, Calif. - August 11, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Under the collabo... 
Printer Friendly Version
08/11/14MannKind Corporation Reports 2014 Second Quarter Financial Results
VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of $30.5 million. In the second quarter of 2014, the settlement terms for certain performance-based a... 
Printer Friendly Version
08/05/14MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
VALENCIA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 11, 2014. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Officer, Hakan Edstrom, and Corpora... 
Printer Friendly Version
06/27/14MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
VALENCIA, Calif., June 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food & Drug Administration (FDA) has approved AFREZZA® (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus. "Approval of AFREZZA is an important milestone for MannKind, as today's FDA action validates the years of clinical research and commitment that powered the development of this unique therapy," said Alfred Mann, Chief... 
Printer Friendly Version
05/27/14MannKind to Present at Upcoming Conferences
VALENCIA, Calif., May 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences. Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 2:30 pm (ET) in New York, New York.   Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014 at 11:20 am (PT) at the Terranea Resort in Rancho Palos Verdes, Califo... 
Printer Friendly Version
05/12/14MannKind Corporation Reports 2014 First Quarter Financial Results
Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, total operating expenses were $41.4 million, compared to $36.4 million for the first quarter of 2013, an increase of $5.0 million. Research and development (R&D) expenses were $26.2 million for the first quarter of 2014, compared to $26.4 million for t... 
Printer Friendly Version
05/07/14MannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference
VALENCIA, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 8:40 am Pacific Time at the Encore at the Wynn Hotel in Las Vegas, Nevada. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Compan... 
Printer Friendly Version
05/05/14MannKind Corporation to Hold 2014 First Quarter Financial Results Conference Call on May 12, 2014
VALENCIA, Calif., May 5, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 first quarter financial results on Monday, May 12, 2014 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 12, 2014. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Officer, Hakan Edstrom, and Corporate Vice P... 
Printer Friendly Version
04/07/14MannKind Updates Status of New Drug Application for AFREZZA(R)
VALENCIA, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA® by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA's requests. About AFREZZA® AFREZZA® (uh-FREZZ-uh) is a novel, ultra rapid-acting mealtime insulin therapy developed by MannKind Co... 
Printer Friendly Version
04/01/14FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes
VALENCIA, Calif., April 1, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve gl... 
Printer Friendly Version
02/19/14MannKind Corporation to Present at Upcoming Conferences
VALENCIA, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences. The RBC Capital Markets 2014 Global Healthcare Conference on February 25, 2014 at 11:30 AM (ET) at The New York Palace in New York, New York.   Cowen and Company 34th Annual Health Care Conference on March 3, 2014 at 3:30 PM (ET) at the Boston Marriott Copley i... 
Printer Friendly Version
02/18/14MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results
Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., Feb. 18, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, total operating expenses were $46.6 million, compared to $33.5 million for the fourth quarter of 2012, an increase of $13.1 million. Research and development (R&D) expenses were $29.0 million for the fourth quarter of 2013, compared... 
Printer Friendly Version
02/04/14MannKind Corporation to Hold 2013 Fourth Quarter and Full Year Financial Results Conference Call on February 18, 2014
VALENCIA, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2013 fourth quarter and full year financial results on Tuesday, February 18, 2014 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on February 18, 2014. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Of... 
Printer Friendly Version
01/10/14MannKind Announces Tentative Date of FDA Advisory Committee Review of AFREZZA
Endocrinologic and Metabolic Drugs Advisory Committee Meeting Tentatively Scheduled for April 1, 2014 VALENCIA, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled on April 1, 2014 to review MannKind's New Drug Application (NDA) for AFREZZA® (insulin human [rDNA origin]) Inhalation Powder. The date and details of the meet... 
Printer Friendly Version
01/08/14MannKind Corporation to Present at the J.P. Morgan 2014 Healthcare Conference
VALENCIA, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the J.P. Morgan 2014 Healthcare Conference on Wednesday, January 15, 2014 at 7:30 AM (PST) at Westin St. Francis Hotel in San Francisco, California. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at... 
Printer Friendly Version


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet